Payment overview · 2025
General Payments
$202.38
12 reported records · 5 companies
Healthcare provider profile · identity verified
David W Allen, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NASHVILLE, TN · NPI 1316933955
Verified facts
What the public records show
CMS Open Payments records show David W Allen, MD received $202.38 in general payments during 2025 across 12 reported records.
Sumitomo Pharma America, Inc. accounted for 35.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $72.11 | 35.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.34 | 25.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.52 | 16.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.09 | 13.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.32 | 9.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $202.38 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $72.11 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.49 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.09 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 40 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
61 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
40 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 333 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 289 | 81 |
| Losartan Potassium | Losartan Potassium | 258 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 254 | 80 |
| Alprazolam | Alprazolam | 250 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 242 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 236 | 67 |
| Prednisone | Prednisone | 204 | 107 |
| Sertraline Hcl | Sertraline Hcl | 168 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 41 |
| Furosemide | Furosemide | 140 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 130 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 30 |
| Gabapentin | Gabapentin | 126 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 116 | 40 |
| Azithromycin | Azithromycin | 115 | 90 |
| Eliquis | Apixaban | 105 | 24 |
| Clonazepam | Clonazepam | 100 | 17 |
| Tramadol Hcl | Tramadol Hcl | 99 | 24 |
| Omeprazole | Omeprazole | 97 | 26 |
| Meloxicam | Meloxicam | 95 | 35 |
| Pregabalin | Pregabalin | 89 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 85 | 16 |
| Simvastatin | Simvastatin | 80 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 78 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 21 |
| Estradiol | Estradiol | 70 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 19 |
| Bupropion Xl | Bupropion Hcl | 68 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 17 |
| Ibuprofen | Ibuprofen | 62 | 21 |
| Mounjaro | Tirzepatide | 61 | 13 |
| Montelukast Sodium | Montelukast Sodium | 60 | 21 |
| Donepezil Hcl | Donepezil Hcl | 55 | 12 |
| Allopurinol | Allopurinol | 52 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 52 | 19 |
| Finasteride | Finasteride | 51 | 15 |
| Levofloxacin | Levofloxacin | 50 | 44 |
| Lisinopril | Lisinopril | 41 | 11 |
| Mirtazapine | Mirtazapine | 41 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 11 |
| Gemtesa | Vibegron | 40 | 13 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Carvedilol | Carvedilol | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Olanzapine | Olanzapine | 38 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 38 | 38 |
| Trazodone Hcl | Trazodone Hcl | 38 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 14 |
| Potassium Chloride | Potassium Chloride | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 33 | 24 |
| Glyburide | Glyburide | 33 | suppressed |
| Methylprednisolone | Methylprednisolone | 33 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Metformin Hcl | Metformin Hcl | 32 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 16 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 29 | 12 |
| Celecoxib | Celecoxib | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Metronidazole | Metronidazole | 27 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Premarin | Estrogens, Conjugated | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | 15 |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 13 |
| Terbinafine Hcl | Terbinafine Hcl | 17 | 11 |
| Telmisartan | Telmisartan | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 13 |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Multaq | Dronedarone Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Viberzi | Eluxadoline | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $202.38 · 12 records | Sumitomo Pharma America, Inc. | AIRSUPRA, Cologuard Collection Kit, FARXIGA, GEMTESA, Ozempic, Rybelsus, Wegovy, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error